When does obinutuzumab’s patent (and exclusivity) expire?
The exact date depends on which country and which specific patent family is being considered (drug substance, formulations, dosing regimens, manufacturing, or method-of-use claims). “Patent loss” can also refer to different legal milestones: patent expiry, loss of market exclusivity, or the ability for competitors to launch a biosimilar.
To give an accurate expiration date, I need at least:
- the country (US, EU, UK, etc.), and
- whether you mean patent expiry or biosimilar market entry/exclusivity expiry.
How does “patent loss” translate into biosimilar market entry?
For biologics like obinutuzumab, competitors typically cannot launch a biosimilar until protections end (for example, one or more patents listed as relevant to the product, and any regulatory exclusivity periods). Once key protections expire or are overturned, the manufacturer can seek approval and then launch, depending on regulatory status and any remaining litigation.
What is obinutuzumab, and why do multiple patents matter?
Obinutuzumab (an anti-CD20 monoclonal antibody used in certain blood cancers) is protected through several types of IP:
- patents on the antibody itself (composition/sequence, engineering),
- manufacturing and process patents,
- formulation and delivery-related patents,
- and sometimes method-of-treatment or dosing-related patents.
Because multiple patents can be in force at the same time, “loss of patent” usually means one or more—but not necessarily all—protections have ended.
Could companies launch in one market while still blocked in another?
Yes. Even if a protection ends in one jurisdiction, other countries can still have active patents or different exclusivity rules. This is common for global biologics because patent filing and enforcement timelines vary by region.
Are there patent disputes or “evergreening” risks around biologics?
Yes, biologics often face litigation and staggered expirations due to additional patents filed later (sometimes called “evergreening” in public debate). The practical impact is that a competitor’s ability to launch can depend on which patents are upheld, dismissed, or settled.
What should you check to find the real “loss of patent” date?
For the most defensible answer, you typically check:
- the product’s regulatory exclusivity status in the target country,
- the patent list tied to that regulatory approval (where applicable),
- and any ongoing injunctions or settlements that affect launch timing.
If you tell me the country (and whether you want “patent expiry” or “biosimilar launch”), I can narrow to the specific milestone you mean and provide the relevant date(s).
Sources
No sources were provided with your prompt, so I can’t cite patent or exclusivity dates yet.